New hope for kids with rare lung condition: inhaled protein therapy in trial
NCT ID NCT06431776
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an inhaled drug called molgramostim in children aged 6 to 18 with autoimmune pulmonary alveolar proteinosis (aPAP), a rare disease where protein builds up in the lungs and makes breathing hard. All 5 participants will take the drug daily via a nebulizer for 12 months. Researchers will check lung function, exercise ability, and quality of life to see if the treatment helps and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
molgramostim (a lab-made protein that helps immune cells clear protein buildup in the lungs)
What this could lead to
If it works, this could point toward a treatment for children with a rare lung disease that currently has limited options.
What could go wrong
This is a very small, early-phase trial with only 5 children, so results may not apply to everyone. The treatment requires daily nebulizer use for a year, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ludwig Maximilians Universität München - Dr. von Haunersches Kinderspital - Kinderklinik und Kinderpoliklinik
RECRUITINGMünchen, 80337, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••